Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report issued on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Trading Down 12.8 %

Shares of Arcadia Biosciences stock opened at $3.46 on Tuesday. The stock has a 50-day moving average price of $2.86 and a 200 day moving average price of $2.75. The company has a market cap of $4.71 million, a P/E ratio of -0.67 and a beta of 1.34. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $4.10.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same period in the prior year, the company posted ($2.64) earnings per share. On average, equities analysts forecast that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.